Guideline review: EASL clinical practice guidelines: drug-induced liver injury (DILI)

Paul N Brennan; Peter Cartlidge; Thomas Manship; John F Dillon

doi:10.1136/flgastro-2021-101886

Guideline review: EASL clinical practice guidelines: drug-induced liver injury (DILI)

Frontline Gastroenterol. 2021 Jul 29;13(4):332-336. doi: 10.1136/flgastro-2021-101886. eCollection 2022.

Authors

Paul N Brennan^{1

2}, Peter Cartlidge³, Thomas Manship⁴, John F Dillon^{3

5}

Affiliations

¹ Centre for Regenerative Medicine, The University of Edinburgh Edinburgh Medical School, Edinburgh, UK.
² Molecular and Clinical Medicine, University of Dundee School of Medicine, Dundee, UK.
³ Department of Gastroenterology, Ninewells Hospital and Medical School, NHS Tayside, Dundee, UK.
⁴ Centre for Liver and Digestive Disorders, NHS Lothian, Edinburgh, UK.
⁵ Molecular and Clinical Medicine, University of Dundee College of Medicine Dentistry and Nursing, Dundee, UK.

Abstract

The European Association for the Study of the Liver has produced extensive guidelines for the investigation and management of drug-induced liver injury. Here, we provide a commentary and overview of some of the principle disease investigations and management that arise from these guideline recommendations.

Keywords: drug induced hepatotoxicity; drug induced liver injury; drug metabolism; drug toxicity.